chartexchange

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

The Motley Fool | Nov 14, 2026 7:05 AM EST

Commercial-stage biotech companies make great investments for those of us looking for both safety and growth. Their portfolios of commercialized products offer a certain degree of revenue stability since patients always need their medicines, regardless of the economic situation. And biotech companies' focus on innovation provides us with the potential for significant growth. Regeneron Pharmaceuticals (NASDAQ: REGN) is one of these players, and shareholders have reaped the rewards over the past year: The stock climbed more than 40%. The company has 16 approved or authorized products in the U.S. and other countries, and these include treatments in immunology, ophthalmology, and oncology. Regeneron's earnings have climbed thanks to this portfolio, and the company also has a solid pipeline to support future earnings growth. Today, with $16 billion in cash and trading around 20x earnings, is Regeneron the cheapest big biotech? Let's find out. Continue reading

Read original article